On April 9, Amatech Medical Devices (Beijing) Co., Ltd. made an announcement that it had successfully concluded its Series D funding round, amassing over 200 million yuan. This funding round was spearheaded by Zhesheng Synergistic Life and Health Fund, with additional contributions from entities such as Henan Key Intellectual Property Fund and Global Hedge Fund Management Co., Ltd. The capital raised will be earmarked for expediting the development of key products. These include the already marketed carbon dioxide non-nephrotoxic contrast imaging device and the fully degradable stent currently under development. Furthermore, the funds will support global market outreach and the establishment of an international strategic framework. Established in 2011, Amatech Medical leverages 3D multi-axis precision printing platform technology to tackle critical diagnostic and therapeutic challenges in vascular disease management. The company offers a comprehensive solution that spans from precise diagnosis to innovative treatment. Its carbon dioxide contrast imaging device has recently obtained approval from the National Medical Products Administration, marking it as the first Class III CO2 contrast injection product in China and addressing a significant void in the domestic market.